Platform built
Nexus CMS is engineered, integrated, and tested. Twenty-five-plus modules covering the full neurodevelopmental pathway — referral through to billing.
Investors
A two-engine business in a category
that is just opening up.
Nexus is a clinical operator and a clinical software company in one. The centre validates the model. The platform scales the model.
Market & opportunity
Demand is exploding.
Supply is stuck.
Recognition of neurodevelopmental conditions is rising sharply across the UK. NHS pathways are saturated. Independent specialist centres are scaling to fill the gap — but doing so on tooling that wasn’t designed for them.
1 in 7
children in the UK are neurodivergent
4+ yrs
average NHS wait for autism assessment
£1.9M
lifetime cost of undiagnosed autism per person
300+
independent UK paediatric specialist centres
Commercial Trajectory
A two-engine business: run the centre, license the platform.
The flagship centre will validate the clinical model and underwrite the platform’s evolution. The platform itself is engineered for dedicated deployment — every install is isolated, compliance-clean, and hosted either on the partner’s own hardware or on a dedicated managed VPS.
Investor enquiries open
1
2026
Pilot phase — platform refined and validated through real clinical workflows at our flagship centre
2
End 2027
Hardened licensing build, partner onboarding tooling, and first external deployments
3
2028
Multi-site licensee rollout across UK independent centres and SEND-aligned services
4
2028+
Continued category leadership and international expansion
The business
Two engines.
One thesis.
Each engine reinforces the other. The centre proves the clinical model and produces revenue. The platform extends that model to other operators and produces recurring licence revenue.
Engine one — the centre
A flagship paediatric neurodevelopmental centre offering consultant-led assessment and multidisciplinary therapy. Validates the clinical model in real-world use; generates clinical revenue from day one.
Engine two — the platform
Nexus CMS, the proprietary clinical management platform built to run that centre. Licensed under dedicated-instance terms to other independent centres, multi-site networks, and SEND-aligned services.
Reinforcing dynamic
Clinical learnings improve the platform. Platform fees fund clinical operations and platform R&D. Each licensee strengthens the moat — clinical, regulatory, and architectural.
Defensible category
We are not building a generic EHR. We are building the category-defining platform for paediatric neurodevelopmental services — with the clinical credibility, the regulatory posture, and the operational depth others cannot replicate quickly.
Traction
Where we are today.
A snapshot of the position entering 2026.
Clinical pilot underway
Live pilot phase running through 2026 - 2027 — refining clinical workflows, intake patterns, and reporting needs through actual use.
Commercial readiness
Licensing pricing, deployment options, partner onboarding programme, and service-level commitments documented and ready.
Compliance posture
GDPR, ICO registration, audit infrastructure, security architecture — all in place. Partner organisations can inherit a defensible posture from day one.
Pipeline forming
Inbound interest from independent centres and SEND-aligned operators. Partner conversations active for end-2027 onboarding.
Roadmap
A clear three-year plan: harden 2026, first onboardings end-2027, multi-site rollout 2028, category leadership beyond.
Where investment goes
Capital deployed against a clear plan.
A focused use of funds across three categories — no scope creep.
Clinical operations
Bringing the flagship centre fully online. Clinical leadership, multidisciplinary team, and the operational footprint to validate the model at scale.
Platform hardening
Production-grade hardening of the platform: scale, security, partner provisioning tooling, and the engineering capacity to support multiple licensee instances.
Partner go-to-market
A small, focused commercial team to convert the pipeline of independent centres and SEND-aligned services through 2027 and 2028.
Investor contact
Open to early conversations.
We share a full investor brief, financial model, and platform walk-through with qualified investors under NDA. The fastest route is a 30-minute introductory call.